ramblings of a mad ramper, page-23

Hi Pat,

Thanks for the post. I just wanted to clarify something you mentioned. While I didn't attend the Investor Briefing, it is my understanding that Alan said the company needed another $50 million bewteen now and achieving cash-flow positive, NOT between now and commencing RTFS production, which is on schedule for March. This is a big difference. The company will now have $35 million of this amount following the CR/SPP, and will also have the ability to finance further capital equipment requirement, should they need to do so.

The prospect of up-front licence/exclusivity fees from additional pharma signing on for RTFS is shaping up as being the ace(s?) in the pack, and as such, tantalising to say the least.

So, all-in-all, as Booster, yourself and others have confirmed with your reports, we are in terrific shape to achieve what will prove to be a watershed year for Unilife in 2011.

All the best.